PMID- 24610583
OWN - NLM
STAT- MEDLINE
DCOM- 20151019
LR  - 20211021
IS  - 0975-0711 (Electronic)
IS  - 0254-8860 (Linking)
VI  - 33
IP  - 4
DP  - 2014 Jul
TI  - Cure rate of Helicobacter pylori infection in Egyptian children related to 
      CYP2C19 gene polymorphism.
PG  - 330-5
LID - 10.1007/s12664-014-0450-6 [doi]
AB  - OBJECTIVES: This study was done in order to investigate the effect of CYP2C19 
      genetic polymorphism on the cure rate of children who received proton pump 
      inhibitors (PPI)-based triple therapy for treating Helicobacter pylori (H. 
      pylori) infection. METHODS: Participants included 100 children with H. 
      pylori-positive gastritis diagnosed by endoscopy and biopsy in addition to H. 
      pylori stool antigen test. Cure rate was assessed after 1 month of completion of 
      a triple treatment course for 14 days. CYP2C19 polymorphism was analyzed by the 
      polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) 
      method. RESULTS: Results showed that cases with a CYP2C19 genotypic status 
      consistent with the heterozygote extensive metabolizers (HetEMs) had a higher 
      cure rate of H. pylori when compared with the homozygote extensive metabolizers 
      (HomEMs) although it was statistically nonsignificant (84.6 vs. 69.2). In 
      addition, the poor metabolizers (PMs) had a higher cure rate compared with those 
      of the HomEMs which was also statistically nonsignificant (77.8 vs. 69.2). The 
      cure rate was also higher among both the groups of HetEMs and PMs combined 
      together compared to the HomEMs (OR = 2.15, p > 0.05). Comparing cases regarding 
      their age, gender, and severity of H. pylori gastritis revealed a better cure 
      rate in the age group >10 years, in females and in mild and moderate cases than 
      other cases although statistically nonsignificant. CONCLUSION: The higher cure 
      rate of H. pylori infection using the triple therapy for 2 weeks among HetEMs and 
      PMs cases compared to the HomEMs might warrant a need for a therapy augmentation 
      or modification for the HomEMs.
FAU - Settin, Ahmad
AU  - Settin A
AD  - Genetics Unit, Mansoura University, Mansoura, Egypt, settin60@gmail.com.
FAU - Abdalla, Ahmad Fathy
AU  - Abdalla AF
FAU - Al-Hussaini, Ayman S
AU  - Al-Hussaini AS
FAU - El-Baz, Rizk
AU  - El-Baz R
FAU - Galal, Amr
AU  - Galal A
LA  - eng
PT  - Journal Article
DEP - 20140308
PL  - India
TA  - Indian J Gastroenterol
JT  - Indian journal of gastroenterology : official journal of the Indian Society of 
      Gastroenterology
JID - 8409436
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 804826J2HU (Amoxicillin)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Amoxicillin/administration & dosage
MH  - Child
MH  - Clarithromycin/administration & dosage
MH  - Cytochrome P-450 CYP2C19/*genetics
MH  - Female
MH  - Gastritis/*drug therapy/enzymology/genetics/*microbiology
MH  - *Helicobacter Infections
MH  - *Helicobacter pylori
MH  - Humans
MH  - Lansoprazole/administration & dosage
MH  - Male
MH  - Polymerase Chain Reaction
MH  - *Polymorphism, Genetic
MH  - Polymorphism, Restriction Fragment Length
MH  - Proton Pump Inhibitors/administration & dosage
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2014/03/13 06:00
MHDA- 2015/10/20 06:00
CRDT- 2014/03/11 06:00
PHST- 2013/09/13 00:00 [received]
PHST- 2014/02/13 00:00 [accepted]
PHST- 2014/03/11 06:00 [entrez]
PHST- 2014/03/13 06:00 [pubmed]
PHST- 2015/10/20 06:00 [medline]
AID - 10.1007/s12664-014-0450-6 [doi]
PST - ppublish
SO  - Indian J Gastroenterol. 2014 Jul;33(4):330-5. doi: 10.1007/s12664-014-0450-6. 
      Epub 2014 Mar 8.